🇺🇸 FDA
Pipeline program

IMFINZI 50 mg/mL concentrate for solution for infusion.

D419QL00009

Phase 3 small_molecule active

Quick answer

IMFINZI 50 mg/mL concentrate for solution for infusion. for small cell lung cancer is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
small cell lung cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials